Annals of Internal Medicine · 1987 · 56 citations · 10 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyDosage Form DesignTreatment PlanningDose SelectionResponse AssessmentMaintenance Therapy Trials
Although danazol is effective in the treatment of idiopathic thrombocytopenic purpura, its long-term safety and optimal dosage are not well established. We compared low (50 mg/d) and conventional (400 to 800 mg/d) dosages in 24 patients. Thirteen patients received the low dose 1 to 24 months after conventional doses had been discontinued (group 1). Five patients received low doses immediately after the conventional doses (group 2). Six patients were treated with low doses from the outset (group 3). In group 1, similar responses to either dose were seen in 9 patients, whereas there were better responses to conventional doses in 3 and to the lower dose in 1. All patients in group 2 maintained remissions with low doses. There were two excellent-good responses, one fair, and three poor responses in group 3. Side effects were generally less frequent and severe with the low doses. Low-dose danazol is better tolerated but took longer to obtain remissions, and is useful for maintenance therapy in the management of idiopathic thrombocytopenic purpura.
10
Danazol for the Treatment of Idiopathic Thrombocytopenic Purpura
Yeon S. Ahn, William J. Harrington, Sheryl R. Simon et al. · New England Journal of Medicine · 1983 · 276 citations
Effect of Danazol in Immune Thrombocytopenic Purpura
Alan D. Schreiber, Paul Chien, Ann Tomaski et al. · New England Journal of Medicine · 1987 · 148 citations
Medicine, Hematology, Pharmacology +13
Long-Term Therapy of Hereditary Angioedema with Danazol
Stephen W. Hosea, María L Santaella, Eric J. Brown et al. · Annals of Internal Medicine · 1980 · 144 citations
Danazol Therapy for Autoimmune Hemolytic Anemia
Yeon S. Ahn, William J. Harrington, Ravindra Mylvaganam et al. · Annals of Internal Medicine · 1985 · 102 citations